We spoke with Amy S. Paller, MD, about her work on how patients’ perceptions regarding the most burdensome aspects of AD on quality of life can differ from those of their physicians.
Trial data of a novel moisturizer containing skin lipids and humectants vs a reference emollient cream without these additives for dry skin treatment is reviewed.
The approval was based on data from three phase 3 trials that evaluated the efficacy and safety of upadacitinib in patients 12 years of age and older with moderate to severe atopic dermatitis who are candidates for systemic therapy.
Data from the Fragile Families and Child Wellbeing Study was reviewed for relationships between atopic dermatitis (AD) and poor school behaviors in younger students.
The demographics, clinical characteristics, patch test results, and occupational data for patients with medical adhesive contact allergy are characterized.
The approval was based on data from 3 pivotal phase 3 (ECZTRA 1-3) trials that evaluated the safety and efficacy of Adbry in 1934 adults with moderate to severe AD.
